Article
Collaborative research conducted by scientists within the Cancer Genome Atlas Research Network have identified significant mutations that can influence tumor subtype classification.
RIT1
MGA
MYC
EGFR
RBM10
NF1
MET
ERBB2
RIT1
MET
Abstract: Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including activating mutations and newly described loss-of-function mutations which are mutually exclusive with focal amplification. mutations were more frequent in female patients, whereas mutations in were more common in males. Aberrations in , , and occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis.
Link to the paper: http://bit.ly/1oFV9OP
Source: Nature
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
Incorporating Discussions of Cannabis Use Into Oncology Care Visits